Zhihong Chi

6.8k total citations · 1 hit paper
171 papers, 3.6k citations indexed

About

Zhihong Chi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Zhihong Chi has authored 171 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Oncology, 78 papers in Molecular Biology and 32 papers in Immunology. Recurrent topics in Zhihong Chi's work include Cutaneous Melanoma Detection and Management (52 papers), Cancer Immunotherapy and Biomarkers (47 papers) and Melanoma and MAPK Pathways (45 papers). Zhihong Chi is often cited by papers focused on Cutaneous Melanoma Detection and Management (52 papers), Cancer Immunotherapy and Biomarkers (47 papers) and Melanoma and MAPK Pathways (45 papers). Zhihong Chi collaborates with scholars based in China, Ethiopia and United States. Zhihong Chi's co-authors include Lu Si, Chuanliang Cui, Xinan Sheng, Jun Guo, Yan Kong, Lili Mao, Bixia Tang, Bin Lian, Jie Dai and Zhan‐You Wang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Zhihong Chi

162 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

2020 192 citations Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhihong Chi China	34	1.9k	1.7k	679	426	401	171	3.6k
Lise Binderup Denmark	40	1.2k 0.6×	1.8k 1.1×	602 0.9×	475 1.1×	235 0.6×	138	5.1k
Paweł Surowiak Poland	32	1.3k 0.7×	2.3k 1.4×	356 0.5×	930 2.2×	622 1.6×	97	3.7k
Soo Ok Lee United States	36	969 0.5×	1.2k 0.7×	510 0.8×	692 1.6×	935 2.3×	62	2.8k
Concetta Bubici United States	21	756 0.4×	2.2k 1.3×	822 1.2×	1.1k 2.6×	338 0.8×	29	3.8k
Peeter Karihtala Finland	28	908 0.5×	1.7k 1.0×	389 0.6×	584 1.4×	285 0.7×	126	3.0k
Stephen Hiscox United Kingdom	36	1.4k 0.7×	2.1k 1.3×	180 0.3×	629 1.5×	353 0.9×	93	3.8k
Wen‐Chun Hung Taiwan	45	1.5k 0.8×	3.1k 1.9×	487 0.7×	1.2k 2.8×	367 0.9×	143	5.3k
Stan Lightfoot United States	33	1.1k 0.5×	1.6k 1.0×	277 0.4×	663 1.6×	311 0.8×	107	3.0k
Patricia Sancho Spain	33	1.4k 0.7×	2.5k 1.5×	608 0.9×	1.3k 3.0×	236 0.6×	61	4.0k
Marco A. De Velasco Japan	33	978 0.5×	1.8k 1.1×	196 0.3×	664 1.6×	632 1.6×	115	3.2k

Countries citing papers authored by Zhihong Chi

Since Specialization

Citations

This map shows the geographic impact of Zhihong Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhihong Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhihong Chi more than expected).

Fields of papers citing papers by Zhihong Chi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhihong Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhihong Chi. The network helps show where Zhihong Chi may publish in the future.

Co-authorship network of co-authors of Zhihong Chi

This figure shows the co-authorship network connecting the top 25 collaborators of Zhihong Chi. A scholar is included among the top collaborators of Zhihong Chi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhihong Chi. Zhihong Chi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Fenghao, Qian Guo, Zhihong Chi, et al.. (2025). Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian. Journal of genetics and genomics. 52(4). 525–538. 2 indexed citations

Zhang, Jiaran, Lili Mao, Caili Li, et al.. (2025). Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. Cancer Management and Research. Volume 17. 905–916. 1 indexed citations

Tang, Bixia, Rong Duan, Xieqiao Yan, et al.. (2024). Natural history of bone-only metastasis in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e17–119.e22. 1 indexed citations

Tang, Bixia, Rong Duan, Xiaoshi Zhang, et al.. (2024). Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The Oncologist. 29(6). e822–e827. 4 indexed citations

Tang, Bixia, Zhihong Chi, Rong Duan, et al.. (2024). Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. The Oncologist. 30(2). 2 indexed citations

Cui, Chuanliang, Yu Chen, Zhiguo Luo, et al.. (2023). Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. BMC Cancer. 23(1). 121–121. 6 indexed citations

Cui, Chuanliang, Xuan Wang, Bin Lian, et al.. (2022). OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer. 10(4). e004307–e004307. 38 indexed citations

Li, Siming, Xiaowen Wu, Xieqiao Yan, et al.. (2022). Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for ImmunoTherapy of Cancer. 10(2). e004036–e004036. 33 indexed citations

Wang, Yue, et al.. (2022). ZnT8 Exerts Anti-apoptosis of Kidney Tubular Epithelial Cell in Diabetic Kidney Disease Through TNFAIP3-NF-κB Signal Pathways. Biological Trace Element Research. 201(5). 2442–2457. 6 indexed citations

10.

Xu, Tianxiao, Jie Dai, Lu Si, et al.. (2021). EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma. Journal of Investigative Dermatology. 142(4). 1158–1170.e8. 26 indexed citations

11.

Yan, Xieqiao, Xinan Sheng, Zhihong Chi, et al.. (2021). Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology. 39(8). 881–889. 36 indexed citations

12.

Cui, Chuanliang, Wenxian Yang, Zhihong Chi, et al.. (2021). Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. npj Genomic Medicine. 6(1). 7–7. 61 indexed citations

13.

Xu, Tianxiao, Sifan Yu, Meng Ma, et al.. (2018). cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients. Translational Cancer Research. 7(2). 248–256. 1 indexed citations

14.

Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127. 72 indexed citations

15.

Kong, Yan, Lu Si, Yiqian Li, et al.. (2015). Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors. Clinical Cancer Research. 22(4). 1018–1027. 58 indexed citations

16.

Zhang, Xiuli, et al.. (2015). Effect of zinc on high glucose-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells. International Journal of Molecular Medicine. 35(6). 1747–1754. 35 indexed citations

17.

Dai, Jie, Yan Kong, Lu Si, et al.. (2013). Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. Clinical Cancer Research. 19(24). 6935–6942. 38 indexed citations

18.

Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498. 121 indexed citations

19.

Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691. 181 indexed citations

20.

Chi, Zhihong, et al.. (2011). A Clinical Characters and Prognosis Analysis on 357 Cases with Cutaneous Malignant Melanoma in China. Zhongliu fangzhi yanjiu. 38(11). 1316–1319. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact